1. Update on pediatric pulmonary arterial hypertension. Differences and similarities to adult disease.
- Author
-
Saji T
- Subjects
- Adult, Age Factors, Age of Onset, Bone Morphogenetic Protein Receptors, Type II genetics, Bone Morphogenetic Protein Receptors, Type II metabolism, Child, Child, Preschool, Female, Humans, Hypertension, Pulmonary epidemiology, Hypertension, Pulmonary genetics, Hypertension, Pulmonary metabolism, Hypertension, Pulmonary pathology, Infant, Infant, Newborn, Male, Syncope epidemiology, Syncope genetics, Syncope metabolism, Syncope pathology, Syncope physiopathology, Vasodilator Agents pharmacokinetics, Vasodilator Agents therapeutic use, Aging, Blood Pressure, Hypertension, Pulmonary physiopathology, Vascular Resistance
- Abstract
Children and adults with pulmonary arterial hypertension (PAH) have similarities and differences in their background characteristics, hemodynamics, and clinical manifestations. Regarding genetic background, mutations in BMPR2-related pathways seem to be pivotal; however, it is likely that other modifier genes and bioactive mediators have roles in the various forms of PAH in children and adults. In pediatric PAH, there are no clear sex differences in incidence, age at onset, disease severity, or prognosis but, as compared with adults, syncope incidence, pulmonary vascular resistance, and mean pulmonary artery pressure are higher, and vasoreactivity to acute drug testing is more frequent, among children. Nevertheless, the pharmacokinetic effects of 3 major pulmonary vasodilators appear to be similar in children and adults with PAH. This review focuses on the specific pathophysiologic features of PAH in children.
- Published
- 2013
- Full Text
- View/download PDF